Results 151 to 160 of about 4,513 (219)

Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD). [PDF]

BMJ Open
Zhang W, Dou Y, Liu J, Liu T, Yan W, Shen Q, Xu H, Zhai Y.   +7 more
europepmc   +1 more source

The Effects of Hypertension Treatment on Heart Rate Variability: A Scoping Review. [PDF]

Cureus
Sehgal D, Bonifanti L, Tran J, Lound M, Manfredi A, Mayrovitz HN.   +5 more
europepmc   +1 more source

FDA Approved pediatric antihypertensive agents [PDF]

, 2014
Doshi, Ashish
core   +1 more source

Exploring the efficacy of some biologically active compounds as anti-hypertensive drugs: an insightful evaluation through DFT, molecular docking and molecular dynamics simulations. [PDF]

In Silico Pharmacol
Majumdar S, Pramanik A.
europepmc   +1 more source

Impact of lifestyle modification practices and pharmacogenetics of <i>ACE I/D</i> gene polymorphism in grade 1 hypertensive patients. [PDF]

J Family Med Prim Care
Rahman F, Elumalai S, Arumugam S, Bhandari A, Prasanth K, Muthiah N, Kumaramanickavel G.   +6 more
europepmc   +1 more source

Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF-κB/NLRP3 signaling pathway. [PDF]

J Tradit Complement Med
Huang R, Luo G, Liu MN, Chen WL, Luo Q, Ma WZ, Xu Y.   +6 more
europepmc   +1 more source

Clinical medication guidance for hypertension personalization through pharmacogenomic research and analysis. [PDF]

Glob Med Genet
Ren Q, Wang S, Ren Y, Liu C.
europepmc   +1 more source

Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study.

Kidney Blood Press Res
Ha X, Gao X, Teng W, Zhang J, Maimaiti Z, Yalikun D, Yang S, Bai L, Caoke T, Jiang H.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fosinopril

Reactions Weekly, 1997
Fosinopril is a phosphorus-containing ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor. It is hydrolysed mainly in the gastrointestinal mucosa and liver to the active diacid, fosinoprilat, which has unique pharmacological properties. The majority of the active moieties of other ACE inhibitors are excreted in the urine.
H, Shionoiri, M, Naruse, K, Minamisawa, S, Ueda, H, Himeno, S, Hiroto, I, Takasaki   +6 more
openaire   +3 more sources